Sanofi: Beyfortus Demonstrates Extended Efficacy Against RSV
Sanofi reports on the results of a population study conducted in Galicia showing that Beyfortus (nirsevimab), its immunization against respiratory syncytial virus, maintains protection in infants beyond their first RSV exposure season. The NIRSE-GAL study, published in The Lancet Infectious Diseases, represents the first prospective real-world evaluation of a universal vaccination program over two consecutive seasons.
Extended Study and Promising Results
The NIRSE-GAL study monitored 11,796 infants (coverage rate of 94.4%) in Galicia, Spain. During the first RSV season, the universal vaccination program with Beyfortus demonstrated a reduction in virus-related hospitalizations. The study also documented a reduction in hospitalizations during the second RSV season among infants immunized in their first season. These results include a decrease in rehospitalizations among infants previously hospitalized for RSV, as well as a reduction in primary care consultations observed during the first season.
Beyfortus: A Comprehensive Immunization Strategy
Beyfortus is presented as an immunization against RSV intended to protect all infants during their first season of virus exposure, including those born at term or prematurely, and those with vulnerability factors. The vaccine is also approved to protect children up to the age of 24 months exposed to a second RSV season. With an extended half-life of 71 days, Beyfortus is administered in a single dose directly to newborns and infants, scheduled to coincide with the RSV season. Since its launch, more than 11 million infants have been vaccinated in over 45 countries.
